Home > Insider Trading > Filing (0000921895-15-002855)

Filing Details

Accession Number:: 0000921895-15-002855
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-12-23 16:50:23
Reporting Period:: 2015-12-21

Filing Date:: 2015-12-23
Accepted Time:: 2015-12-23 16:50:23
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1540729	Foresight Energy Lp	FELP	Bituminous Coal & Lignite Mining (1220)	800778894

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1211729	Accipiter Life Sciences Fund Lp	C/O Candens Services, Inc. 525 Washington Blvd., 33Rd Floor Jersey City NJ 07310	No	No	Yes	No
1214706	Ltd Offshore Fund Sciences Life Accipiter	C/O Candens Services, Inc. 525 Washington Blvd., 33Rd Floor Jersey City NJ 07310	No	No	Yes	No
1280190	Accipiter Capital Management, Llc	3801 Pga Blvd. Suite 600 Palm Beach Gardens FL 33408	No	No	Yes	No
1322420	Gabe Hoffman	3801 Pga Blvd. Suite 600 Palm Beach Gardens FL 33408	No	No	Yes	No
1351609	Candens Capital Llc	3801 Pga Blvd. Suite 600 Palm Beach Gardens FL 33408	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Units	Acquisiton	2015-12-21	2,345	$2.82	3,500,756	No	4	P	Indirect	By Accipiter Life Sciences Fund, LP
Common Units	Acquisiton	2015-12-21	2,162	$2.82	4,682,029	No	4	P	Indirect	By Accipiter Life Sciences Fund (Offshore), Ltd.
Common Units	Acquisiton	2015-12-22	10,399	$2.89	3,511,155	No	4	P	Indirect	By Accipiter Life Sciences Fund, LP
Common Units	Acquisiton	2015-12-22	9,588	$2.89	4,691,617	No	4	P	Indirect	By Accipiter Life Sciences Fund (Offshore), Ltd.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Accipiter Life Sciences Fund, LP
No	4	P	Indirect	By Accipiter Life Sciences Fund (Offshore), Ltd.
No	4	P	Indirect	By Accipiter Life Sciences Fund, LP
No	4	P	Indirect	By Accipiter Life Sciences Fund (Offshore), Ltd.

Footnotes

This Form 4 is filed jointly by Accipiter Life Sciences Fund, LP ("ALS Fund"), Accipiter Life Sciences Fund (Offshore), Ltd. ("ALS Offshore"), Accipiter Capital Management, LLC ("Accipiter Management"), Candens Capital, LLC ("Candens Capital"), and Gabe Hoffman (collectively, the "Reporting Persons").
Each Reporting Person may be deemed to be a member of a group that owns more than 10% of the Issuer's outstanding Common Units. Each Reporting Person disclaims beneficial ownership of the Common Units reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such Common Units for purposes of Section 16 or for any other purpose.
Common Units directly owned by ALS Fund. Accipiter Management, as the investment manager of ALS Fund, may be deemed to be the beneficial owner of the Common Units directly owned by ALS Fund. Each of Candens Capital, as the general partner of ALS Fund, and Mr. Hoffman, as the managing member of each of Candens Capital and Accipiter Management, may be deemed to be the beneficial owner of the Common Units directly owned by ALS Fund.
Common Units directly owned by ALS Offshore. Accipiter Management, as the investment manager of ALS Offshore, may be deemed to be the beneficial owner of the Common Units directly owned by ALS Offshore. Mr. Hoffman, as the managing member of Accipiter Management, may be deemed to be the beneficial owner of the Common Units directly owned by ALS Offshore.
The price reported in Column 4 is a weighted average price. These Common Units were purchased in multiple transactions at prices ranging from $2.82 to $2.83. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Units purchased at each separate price within the ranges set forth in footnotes 5 and 6 to this Form 4.
The price reported in Column 4 is a weighted average price. These Common Units were purchased in multiple transactions at prices ranging from $2.85 to $2.93. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Units purchased at each separate price within the ranges set forth in footnotes 5 and 6 to this Form 4.